p.11 抽出テキスト

Table 3 What is new

New or revised Recommendations in 2013 version Class Recommendations in 2021 version Class Risk factors and clinical conditions  section 3 New In apparently healthy people <70 years of age without established ASCVD, DM, CKD, genetic/rarer lipid or BP disorders, estimation

of 10-year fatal and nonfatal CVD risk with SCORE2 is recommended. I

New In apparently healthy people >_70 years of age without established ASCVD, DM, CKD, genetic/rarer lipid or BP disorder, estimation

of 10-year fatal and nonfatal CVD risk with SCORE2-OP is recommended. I

New Patients with established ASCVD and/or DM and/or moderate-

to-severe renal disease and/or genetic/rarer lipid or BP disorders are to be considered at high or very high CVD risk. I

New A stepwise treatment-intensification approach aiming at intensive risk factor treatment is recommended for apparently healthy peo-

ple at high or very high ASCVD risk, as well as patients with established ASCVD and/or DM, with consideration of CVD risk, treatment benefit of risk factors, risk modifiers, comorbidities, and patient preferences. I

New Treatment of ASCVD risk factors is recommended in apparently healthy people without DM, CKD, genetic/rarer lipid or BP disor-

ders who are at very high CVD risk (SCORE2 >_7.5% for age under 50; SCORE2 >_10% for age 5069; SCORE2-OP >_15% for age >_70). I

New An informed discussion about CVD risk and treatment benefits

tailored to the needs of a patient is recommended. I

New It is recommended that mental disorders with either significant functional impairment or decreased use of healthcare systems be

considered as influencing I

New Treatment of ASCVD risk factors should be considered in appa-

rently healthy people without DM, CKD, genetic/rarer lipid, or BP disorders who are at high CVD risk (SCORE2 2.5 to <7.5% for age under 50; SCORE2 5 to <10% for age 5069; SCORE2-OP 7.5 to <15% for age >_70 years), taking ASCVD risk modifiers, lifetime risk and treatment benefit, and patient preferences into account. IIa

New In apparently healthy people, after estimation of 10-year fatal and non-fatal CVD risk, lifetime risk and treatment benefit, risk modi-

fiers, frailty, polypharmacy, and patient preferences should be considered. IIa

New Presence of migraine with aura should be considered in CVD risk assessment. IIa New Assessment of CVD risk should be considered in men with ED. IIa New In women with a history of premature or stillbirth, periodic

screening for hypertension and DM may be considered. IIb

New Assessment of total CVD risk may be considered in adults with

chronic inflammatory conditions. IIb

New Avoidance of combined hormonal contraceptives may be consid-

ered in women with migraine with aura. IIb

Risk factors and interventions at the individual level  section 4 New It is recommended to reduce sedentary time to engage in at least

light activity throughout the day to reduce all-cause and CV mortality and morbidity. I

Continued Downloaded from academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 07 October 2026